RxCelerate Ltd has acquired Total Scientific Ltd, a contract research organisation.

The Total Scientific brand will be withdrawn and the company’s services will be provided only through RxCelerate, upon completion of the acquisition.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Based in the UK, RxCelerate is an outsourced drug development company.

The acquisition will improve RxCelerate’s position in the outsourced drug development market.

HealthCare Global Enterprises Ltd has agreed to purchase a 12% share in International Stemcell Services Ltd (ISSL) for Rs5.61m ($84,000).

HealthCare Global Enterprises will buy 10,860 equity shares from the existing shareholders of ISSL as part of the deal.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“HealthCare Global Enterprises will buy 10,860 equity shares from the existing shareholders of ISSL as part of the deal.”

Based in India, HealthCare Global Enterprises is engaged in the provision of cancer care services.

REPROCELL Incorporated has acquired BioServe Biotechnologies (India) Private Limited from Cancer Genetics Inc for $1.9m.

REPROCELL has made an upfront payment of $1.6m in cash to Cancer Genetics as part of the transaction.

The company will pay the remaining amount based on BioServe’s revenue for a four-month period being similar to that of the same period in 2017.

Based in India, REPROCELL Incorporated is a biomedical research company, while BioServe is a DNA extraction, synthesis, sequencing and related services provider.

Raymond James & Associates Inc was appointed as the financial adviser for the transaction by Cancer Genetics.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact